Form 4: Eli Lilly Director Sulzberger Acquires Shares Under Directors' Deferral Plan

Director Gabrielle Sulzberger acquired 6.061 shares of Eli Lilly & Co. common stock under the company's Directors' Deferral Plan.

Summary

• On April 21, 2025, Gabrielle Sulzberger, a director of Eli Lilly & Co., acquired 6.061 shares of common stock at a price of $818.02 per share.
• The shares were acquired under the Lilly Directors' Deferral Plan in lieu of cash compensation.
• Following the transaction, Sulzberger directly owns 2,562.085 shares of Eli Lilly & Co.
• The acquired shares will be settled in shares of common stock following Sulzberger's separation from service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The acquisition of shares by a director is generally viewed as a positive sign, indicating confidence in the company's future. However, it's a routine transaction related to director compensation.

Positives

• The acquisition of shares by a director signals confidence in the company's future performance.

Future Outlook

The acquired shares will be settled in shares of common stock following Sulzberger's separation from service.

Industry Context

Director share acquisitions are common in publicly traded companies and are often seen as a positive sign of management's confidence in the company's prospects. The Lilly Directors' Deferral Plan is a mechanism for directors to receive compensation in the form of company stock, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Director compensation packages often include stock options or deferred stock units to align director interests with shareholder value.
• The Lilly Directors' Deferral Plan is similar to deferred compensation plans offered by other large pharmaceutical companies such as Pfizer (PFE) and Johnson & Johnson (JNJ).

Stakeholder Impact

• The acquisition of shares by a director can positively influence shareholder sentiment.

Key Dates

Keywords

Form 4, Director, Share Acquisition, Eli Lilly, LLY, Sulzberger, Directors' Deferral Plan, Common Stock